An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05055024 |
Recruitment Status :
Completed
First Posted : September 23, 2021
Last Update Posted : March 13, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Narcolepsy With Cataplexy Narcolepsy Narcolepsy Without Cataplexy | Drug: Mazindol | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 52 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A 6-Month Multicenter, Open-Labelled Extension of the Clinical Trial NLS-1021 in Narcoleptic Patients With and Without Cataplexy |
Actual Study Start Date : | October 26, 2021 |
Actual Primary Completion Date : | January 19, 2023 |
Actual Study Completion Date : | January 19, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: NLS-2 (mazindol extended release)
NLS-2 (mazindol extended release) administered once a day.
|
Drug: Mazindol
Drug: NLS-2
Other Names:
|
- To evaluate the safety and tolerability of NLS-2 in adult subjects with narcolepsy type 1 (NT1) or narcolepsy type 2 (NT2) [ Time Frame: 24 weeks ]Summaries of the number and percentage of subjects who experienced Treatment Emergent Adverse Events (TEAEs), TEAEs related to study drug, SAEs, or discontinued study drug or withdrew from the study due to an AE.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- The subject must complete all Study NLS-1021 study requirements and assessments up to Visit 6;
- The subject is able, in the opinion of the Investigator, to receive NLS-2 for the 24-week Treatment Phase of this study;
- Biological females of childbearing potential must agree to use a medically acceptable double-barrier method of contraception for at least 30 days prior to Day 1 and until completion of the study;
- The subject is able to comply with the open-labelled extension design schedule and other study requirements;
- The subject provides written informed consent for the open-label extension study.
Exclusion Criteria:
- The subject meets any Exclusion Criteria for Study NLS-1021 at Visit 6 of that study;
- The subject receives any investigational drug (other than the COVID-19 vaccine) that is not NLS-2.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05055024
Study Director: | Carlos Camozzi, MD | NLS Pharmaceutics |
Responsible Party: | NLS Pharmaceutics |
ClinicalTrials.gov Identifier: | NCT05055024 |
Other Study ID Numbers: |
NLS-1022 |
First Posted: | September 23, 2021 Key Record Dates |
Last Update Posted: | March 13, 2023 |
Last Verified: | March 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Narcolepsy Cataplexy Disorders of Excessive Somnolence Sleep Disorders, Intrinsic Dyssomnias Sleep Wake Disorders Nervous System Diseases Mental Disorders Mazindol Central Nervous System Stimulants |
Physiological Effects of Drugs Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Adrenergic Agents Neurotransmitter Agents Dopamine Uptake Inhibitors Dopamine Agents |